Psychedelic Alpha

On Monday, the day FDA’s Considerations for Potential Future Therapeutic Use of Psychedelic Drugs public comment period closed, the agency issued a request for information (RFI) related to clinical studies of ibogaine. In the notice, FDA outlines a potential early-stage ibogaine clinical trial design, which it says is consistent with its final guidance for clinical investigat...

Welcome to our Q3 2026 Quarterly Briefing. Every three months, our Founder & Editor Josh Hardman walks you through major developments from the prior quarter across drug development, policy and regulation, science and academia, and much more. He closes with a look ahead to the next quarter, so you know what to look out for.

Now that federal lobbying data from the second quarter of the year is available to retrieve, we present our regular update on the state of activity across psychedelic drug developers and nonprofits. Psychedelics companies’ spending on lobbying firms at the federal level reached new heights in Q2 2026, though the aggregate amount (just shy of $350,000) remains relatively modes...